ד"ר מיה קורן-מיכוביץ היא בוגרת הפקולטה לרפואה באוניברסיטת ת"א וסיימה את ההתמחות ברופאה פנימית ובהמטולוגיה בבית החולים אסף הרופא. ד"ר קורן-מיכוביץ סיימה 3 שנות מחקר בבית החולים Cedars Sinai בלוס אנגלס אצל פרופסור Phil Koeffler. ד"ר קורן-מיכוביץ הינה רופאה בכירה במערך ההמטולוגי בבית החולים שיבא, תל השומר והיא מנהלת מחקר מעבדתי בסיסי ומחקר קליני בחולים עם ממאירויות המטולוגיות.
1. הבסיס המולקולרי של ממאירויות המוטולוגיות
2. מחלות מילופרוליפרטיביות
3. לויקמיה חריפה וכרונית
1. Koren-Michowitz M, Eting E, Rahimi-Levene N, Garach-Jehoshua O, Volcheck Y, Kornberg A. Protein Z levels and central retinal vein or artery occlusion. Eur J Haematol 2005;75:401-405.
2. Koren-Michowitz M, Friedman E, Gershoni-Baruch R, et al. . Coinheritance of BRCA1 and
BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish
population: possible role in risk modification for cancer development. Am J Hematol
2005;78:203-206.
3. Koren-Michowitz M, Rahimi-Levene N, Volcheck Y, Garach-Jehoshua O, Kornberg A. Protein Z and its role in venous and arterial thrombosis. Isr Med Assoc J 2006;8:53-55.
4. Koren-Michowitz M, Rahimi-Levene N, Volcheck Y, Hardan I, Kornberg A. Rituximab
monotherapy as interim therapy in precursor B-ALL adults during periods of hepatic toxicity:
report of two cases. Am J Hematol 2006;81:979-980.
5. Koren-Michowitz M, Hardan I, Berghoff J, et al. Chromosome 13q deletion and IgH
abnormalities may be both masked by near-tetraploidy in a high proportion of multiple myeloma patients: a combined morphology and I-FISH analysis. Cancer Lett 2007;255:307-314.
6. Vivante A, Amariglio N, Koren-Michowitz M, et al. High-throughput, sensitive and quantitative
assay for the detection of BCR-ABL kinase domain mutations. Leukemia 2007;21:1318-1321.
7. Ashur-Fabian O, Trakhtenbrot L, Dominissini D, et al. The presence of a single PML-RARA
isoform lacking exon 5 in FISH-negative APL samples. Leukemia 2008;22:200-203.
8. Benjamini O, Koren-Michowitz M, Amariglio N, Kroger N, Nagler A, Shimoni A. Relapse of
postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic
phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test
for V617F-JAK2 mutation. Leukemia 2008;22:1961-1963.
9. Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-
011, a humanized antibody interacting with PD-1, in patients with advanced hematologic
malignancies. Clin Cancer Res 2008;14:3044-3051.
10. Koren-Michowitz M, Shimoni A, Vivante A, et al. A new MALDI-TOF-based assay for
monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell
transplantation (allo SCT) for classic myeloproliferative disorders (MPD). Leuk Res 2008;32:421-
427.
11. Amariglio N, Hirshberg A, Scheithauer BW, et al. . Donor-derived brain tumor following
neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 2009;6:e1000029.
12. Shimoni A, Leiba M, Schleuning M, et al. Prior treatment with the tyrosine kinase inhibitors
dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase
and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and
philadelphia positive acute lymphoblastic leukemia. Leukemia 2009;23:190-194.
13. Gueller S, Goodridge HS, Niebuhr B, et al. Adaptor protein Lnk inhibits c-Fms-mediated
macrophage function. J Leukoc Biol 2010;88:699-706.
14. Koren-Michowitz M, le Coutre P, Duyster J, et al. Activity and tolerability of nilotinib: a
retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib
resistant or intolerant. Cancer 2010;116:4564-4572.
15. Thoennissen NH, Krug UO, Lee DH, et al. Prevalence and prognostic impact of allelic
imbalances associated with leukemic transformation of Philadelphia chromosome-negative
myeloproliferative neoplasms. Blood 2010;115:2882-2890.
16. Trakhtenbrot L, Hardan I, Koren-Michowitz M, et al. Correlation between losses of IGH or its
segments and deletions of 13q14 in t(11;14) (q13;q32) multiple myeloma. Genes Chromosomes
Cancer 2010;49:17-27.
17. Avni B, Koren-Michowitz M. Myeloid sarcoma: current approach and therapeutic options.
Therapeutic Advances in Hematology 2011;2:309-316.
18. Chan D, Koren-Michowitz M. Update on JAK2 inhibitors in myeloproliferative neoplasm.
Therapeutic Advances in Hematology 2011;2:61-71.
19. Hardan I, Stanevsky A, Volchek Y, et al. Treatment with Interferon alpha prior to
discontinuation of Imatinib in patients with chronic myeloid leukemia. Cytokine 2011.
20. Koren-Michowitz M, Sato-Otsubo A, Nagler A, Haferlach T, Ogawa S, Koeffler HP. Older
patients with normal karyotype acute myeloid leukemia have a higher rate of genomic changes compared to young patients as determined by SNP array analysis. Leuk Res 2011.
21. Koren-Michowitz M, Volchek Y, Naparstek E, et al. . Imatinib plasma trough levels in chronic
myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC. Hematol Oncol 2012.
22. M Koren-Michowitz, J Landman, Y Cohen, N Rahimi-Levene, O Salomon, M Michael, N
Amariglio, A Nagler. JAK2V617 Allele Burden is Associated with Transformation to Myelofibrosis.
Leuk Lymphoma 2012.
